Skip to main content
Clinical Trials/NCT05237804
NCT05237804
Completed
Not Applicable

Evaluation d'Une Intervention Pour Reduire le Delai de Traitement Des Patients Traites Par TAVI

University Hospital, Rouen2 sites in 1 country828 target enrollmentOctober 26, 2022

Overview

Phase
Not Applicable
Intervention
Control group
Conditions
Aortic Valve Stenosis
Sponsor
University Hospital, Rouen
Enrollment
828
Locations
2
Primary Endpoint
To evaluate the effectiveness of an intervention combining a patient component and an organisational component
Status
Completed
Last Updated
2 months ago

Overview

Brief Summary

Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population. Although significant progress has been made in understanding the pathophysiological mechanisms underlying the onset and progression of AS, there is no medical treatment to slow or prevent its progression. The only treatment available is Aortic Valve Replacement (AVR) performed by surgery or by catheterization (TAVI).

Once a diagnosis has been made and the decision to treat these patients has been taken, the procedure (AVR or TAVI) must be performed rapidly given the poor prognosis of the disease without treatment. Studies have shown that on the waiting list, the probability of death and hospitalisation for heart failure increases with time. This delay could also reduce the effectiveness of TAVI, thus affecting the performance of the healthcare system.

In this study, an intervention combining an e-health component (tool intended for patients, families and health professionals in contact with patients), and an organisational component (for TAVI implanting centres) has been designed. The aim of this study is to evaluate the effectiveness of this intervention.

Registry
clinicaltrials.gov
Start Date
October 26, 2022
End Date
October 23, 2025
Last Updated
2 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Hospital, Rouen
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient over 18 years of age;
  • Aortic stenosis
  • Indication of TAVI
  • Patient affiliated or benefiting from a health insurance scheme
  • Patient having read and understood the information letter and having signed the consent form

Exclusion Criteria

  • TAVI indication not retained
  • Patient who are not fluent in French and have no one around them to translate,
  • Patient who do not have access to the Internet (at home or in their immediate environment)
  • Proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective contraception (as defined by the WHO) or postmenopausal woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ;
  • Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curators
  • History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his informed consent

Arms & Interventions

Control group

The randomized centres in this group will not change their practices.

Patient component

The randomized centres in this group will be required to present patients with: * A short introductory video, viewed on a tablet during hospitalization for coronary angiography, * A paper booklet, * A website.

Intervention: Patient component

Organisational component

The randomized centres in this group will be provided with a list of organisational changes to be implemented to improve patient care times.

Intervention: Organisational component

Patient and organisational components

The randomized centres in this group will have to implement the two components.

Intervention: Patient component

Patient and organisational components

The randomized centres in this group will have to implement the two components.

Intervention: Organisational component

Outcomes

Primary Outcomes

To evaluate the effectiveness of an intervention combining a patient component and an organisational component

Time Frame: Month 6

Percentage of patients with a TAVI indication with a time to TAVI procedure of less than 2 months

Secondary Outcomes

  • Intervention components' adaptation(Month 6)
  • Patients' health-related quality of life(Baseline, Months 3 and 6)
  • Medication compliance(Month 6)
  • Number of visits to the patient section of the website(Month 6)
  • Acceptability of the intervention for participating centers(Month 6)
  • Time to care, in days(Month 6)
  • Mortality rate(Months 3 and 6)
  • Intervention components' dose and fidelity(Month 6)
  • Incremental cost-effectiveness ratio(Month 6)
  • Patient knowledge of the disease and the TAVI procedure(Baseline, Month 3)
  • Patient satisfaction(Month 6)
  • Reached populations(Month 6)
  • Number of visits to the professional section of the website(Month 6)

Study Sites (2)

Loading locations...

Similar Trials